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Enzyme catalysis powered micro/nanomotors for
biomedical applications
Motilal Mathesh,† Jiawei Sun† and Daniela A. Wilson *
With recent developments in the field of autonomous motion for artificial systems, many researchers are
focusing on their biomedical application for active and targeted delivery. In this context, enzyme
powered motors are at the forefront since they can utilize physiologically relevant fuels as their
substrate and carry out catalytic reactions to power motion under in vivo conditions. This review
focuses on the design and fabrication of enzyme powered motors together with their propulsion
mechanism by using fuels present in biological environments. In addition, the recent advances in the
field of enzyme powered motors for biomedical applications have been discussed together with the
parameters that need to be considered for designing such systems. We believe that this review will
provide insights and better understanding for the development of next generation biomedical
technologies based on enzyme powered motors.
1. Introduction
Nanotechnology has played a crucial role over the past few
decades in the development of nanomedicine, from targeted
drug delivery, therapeutics, and diagnostic agents to the fabri-
cation of biosensors and medical devices for maximizing their
positive responses while minimizing side effects.1 In the past
decade, micro/nanomotors (MNMs) have been proved to be a
potential tool for addressing complicated in vivo problems, such
as drug delivery, cell sensing, imaging, wound healing and tissue
uptake. Compared to passive diffusion, active motion is powerful
and shows faster cargo delivery and overcomes drawbacks
such as systemic toxicity and reliance on passive diffusion for
transport.2 The idea of fabricating artificial motors is inspired
from biological motors in living systems that are ubiquitous and
capable of performing precise tasks like intracellular transport,
cell division, and cell locomotion by converting chemical energy
into mechanical force.3 One of the typical examples is kinesin,
a motor protein, that is able to walk along microtubules by
unbinding and rebinding to the filaments through adenosine
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triphosphate (ATP) hydrolysis.4,5 In past decades, tremendous
progress has been made in developing hybrid (biological and
non-biological) devices with ATP-dependent motor proteins such
as kinesin, myosin, and dynein. Back in 2001, Vogel et al.
developed a molecular shuttle with kinesin protein motors,
capable of moving cargo along an engineered pathway using
ATP as a fuel.6 Whitesides et al. designed a synthetic motor
powered by hydrogen peroxide (H2O2) in which platinum (Pt)
was introduced on the surface of the motor as a catalyst to
decompose H2O2, resulting in an impulse of oxygen bubbles for
autonomous motion.7 Since then mimicking the behavior of bio-
motors and bio-organisms by synthetic motors with catalysts has
attracted considerable attention, together with intensive studies
towards the realization of fuel dependent self-propulsion of
synthetic MNMs.8 H2O2 has been widely used as a fuel because
of the production of oxygen, while Pt has also become a popular
catalyst. Besides, H2O2, hydrazine,
9 water,10 acid,11 base,12 and
bromine (iodine)13 have also been used as fuels for propelling
the motors, with iridium (Ir), aluminum (Al), zinc (Zn),
Al/palladium (Pd) and Pt being used as catalysts.
In spite of great progress in this field, we are still far from
using motors for in vivo tasks due to the bottlenecks present.
The main limitations are their ability to move in biological
fluids, the size and the poor biocompatibility of both materials
used for fabrication and the fuels used for active motion.14
For biomedical applications, enzymes are ideal candidates
as catalysts that can power the motors because of their bio-
compatibility, high turnover numbers and great selectivity
under physiological conditions.15,16 Back in 2005, Heller et al.
reported the propulsion of carbon microfibers at an air–glucose
interface by the ion flow produced by a catalytic reaction, using
glucose oxidase (GOx) and bilirubin oxidase (BOD) as catalysts.17
From then on, more and more enzymes have been introduced in
the intelligent systems as biocatalysts for developing enzyme-
powered motors (EPMs), such as catalase,18,19 urease,20–22 atpase,23
lipase24 etc. Besides biocatalysts, the use of biocompatible
substrates is also essential, in particular, the ones present in
living systems are considered as good candidates. Motors with
proof of concept studies relying on toxic fuels limit their use for
biomedical application, since it is not possible to use them
in in vivo scenarios.25 Moreover, the external addition of
substrates to the biological system seems unrealistic, with their
safety issues that need to be evaluated. To have a better view of
this field, several reviews have been published recently. The
mimicking of natural motility behaviour using synthetic soft
materials has been discussed by Samuel Sanchez et al.26 The
biocompatibility of propulsion techniques has been discussed
by Halder and Sun.27 Several reviews towards biomedical
applications have also been published. In 2018, Guan et al.
discussed the use of micro/nanorobots for active drug
delivery.28 Besides, Soto et al. discussed the use of micro/
nanomotors for medical applications and emphasized the current
and foreseeable perspectives of their commercialization.29 More-
over, the importance of biocompatibility of motors for biomedical
applications has also been discussed by Peng et al.30 As a
promising catalyst candidate, using enzyme to power micro- and
nanoswimmers has been discussed by Sanchez et al.31 and Sen
et al.15 An overview of most recent advances of micro/nanomotors
has been discussed by Sta¨dler et al.32 However, of all the reviews,
using enzyme motors for biomedical applications has not been
discussed. The importance of biofuels and the accessibility of
biofuels for in vivo powering motors are also essential for the
future perspectives of enzyme powered motors.
Our discussion in this review will first focus on the biologi-
cal fuels available in biological systems and will highlight
several possibilities of using them for motion, as they are not
adequately reported in the literature. Besides, several popular
biocatalysts that can carry out catalytic reactions using these
biological fuels as substrates are provided. As already described
before, MNMs equipped with inorganic catalysts will not be
discussed here as it is not the scope of this review.33,34 The
chemotaxis behavior of EPMs is also discussed, as they are
essential for further biomedical applications. Finally, the recent
progress on EPMs as well as their biomedical applications
based on the material used for fabrication has been addressed.
At the end, an outlook of current challenges and future pro-
spects to enable them for in vivo applications is discussed. We
believe that this review will lay a platform for the design and
fabrication of autonomous, intelligent and stimuli responsive
systems for next generation in vivo focused MNMs.
2. Fuels in biological environments
Using enzyme-powered micro/nanomotors for biomedical appli-
cations holds great promise for many medical challenges, such
as targeted drug delivery, bio-sensing and imaging. Designing
such a system has quite some restrictions, with primary
challenges such as the fuels that can be used, whether the
fuels are available in a biological system and whether the
fuel concentration (conc.) can support the motion of motors,
therefore warranting the urgent search for a ‘‘green fuel’’
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present in the biological system. Furthermore, the biological
microenvironment with pH and temperature changes also needs
to be considered, and also whether the addition of fuels to the
system could change the microenvironment or if the product from
the catalytic reactions could induce a toxic response in our body
should be studied.33,35 In the next section, we are going to look at
the possible fuels for MNMs that can be used for biomedical
applications and discuss their possible associated risks.
2.1 Hydrogen peroxide (H2O2)
As a reactive oxygen species (ROS), H2O2 is involved in a wide
variety of physiological functions, from cytokine, insulin and
AP-1 signaling to redox regulation.36–40 H2O2 is present in all
aerobic metabolism, and it is generated through a variety of
extracellular and intracellular actions. The biochemical path-
ways for the generation and metabolism of H2O2 have been
reported by Hua Cai40 (Fig. 1a) showing that the mitochondrial
electron transport chain, the arachidonic acid metabolizing
enzymes lipoxygenase and cycloxygenase, the cytochrome
P450s, xanthine oxidase, NAD(P)H oxidases, uncoupled nitric
oxide synthase (NOS) and peroxidases can all be possible ROS
enzymatic sources, which is also supported by other research
studies.39–43 However, it is noteworthy that H2O2 is also con-
sidered to be a cytotoxic agent, and it can be harmful to cells
when it reaches certain conc. (B50 mM), resulting in the
oxidation of DNA, lipids and proteins.44,45
Recent progress in MNMs has made H2O2 an important fuel
in powering micro/nanomotors, since they can be decomposed
into water (H2O) and oxygen (O2) bubbles (2H2O2- 2H2O + O2),
in which oxygen bubbles provide the thrust to propel motors.46
The propulsion mechanism associated with these systems is the
so-called bubble propulsion, in which the fuel can be decom-
posed by a motor equipped with catalysts to form micron sized
gas bubbles and released from the motor surface, thus driving
the motor directionally away from the catalyst.35 The most widely
used biocatalysts for the decomposition of H2O2 are Pt and
catalase (EC 1.11.1.6),16 of which catalase being one of the most
efficient enzymes reported is suggested for biomedical applica-
tions because of its biocompatibility and high turnover rate
(kcat = 2.12  105 s1).47,48 Moreover, research studies have also
shown that human tumor cells produce more H2O2 than normal
cells,49,50 as high conc. of ROS is required for promoting cell cycle
progression and differentiation.51–53 The difference in conc.
between normal cells and tumor cells may create a gradient of
H2O2, which helps motors to perform chemotaxis behavior for
achieving targeted delivery.56 However, whether H2O2 present in
tumor tissues would promote themotion ofmotors still needs to be
investigated, since most of the studies rely on the addition of fuels
externally with almost no in vivo effect reported to the best of our
knowledge. Moreover, the amount of fuel needed for the motor
sustained motion is variable, and the differences in size and
materials can also influence the motion behavior.
2.2 Urea
Urea (CO(NH2)2) is an essential metabolite containing nitrogen
in the human body, produced by the metabolic transformations
and catabolism of amino acids, to eliminate the generated
nitrogen as the waste in our body. It is mainly expressed in
the liver by the so-called urea cycle54 (Fig. 1b), in which five
enzymes are involved: carbamoyl phosphate synthetase-I (CPS-I),
ornithine transcarbamylase, argininosuccinate synthetase (ASS),
argininosuccinate lyase (ASL), and arginase.57,58 After being
produced in the liver, urea is then transported from the blood
and excreted mostly through urine by the kidneys, with some
being hydrolyzed to ammonia in the lumen of the large intestine
by urease-producing bacteria.59,60 The blood urea conc. in the
human body was reported by MacKay et al. in 1927,61 to be
29.3 mg of urea in 100 cc of blood (E5 mM) on average, and
studies from other groups have also reported similar results.62
Furthermore, the conc. in urine can vary but it is much higher
than in plasma, and Bailly et al.63 reported a conc. of 1.91 g L1
(E30 mM) while Raftery et al.62 recently reported the conc. To
be around 126 mM. Moreover, the increase of urea conc. in
plasma might relate to the imbalance between production and
excretion, which can indicate several diseases, such as chronic-
persistent hepatitis (CPH), chronic-active hepatitis (CAH) and
liver cirrhosis.64,65
Urea has become a popular fuel in powering motors in recent
years, and it can be hydrolyzed by urease into ammonium ions
(NH4
+) and bicarbonate anions (HCO3
). Interestingly, a study
Fig. 1 (a) Biochemical pathways of H2O2 generation and metabolism.
Molecular oxygen undergoes one or two-electron reduction (1 or 2 e)
to form superoxide (O2
) or H2O2, respectively. The degradation of H2O2
involves intracellular catalase (CAT), extracellular glutathione peroxidase
(GPX) or small molecules like thiols.40 (b) Formation of urea from carbon
dioxide and ammonia within the hepatocyte. Bicarbonate is formed from
carbon dioxide by the action of carbonic anhydrase (CA).54 (c) Electrons
are transferred from NADH dehydrogenase to cytochrome c oxidase by
coenzyme Q (Q), the cytochrome bc1 complex and cytochrome c. The
established proton gradient across the inner mitochondrial membrane
drives the proton flow in ATP synthase that accompanies ATP synthesis.55
Adapted with permission from ref. 40. Copyright 2002 Oxford University
Press. Adapted with permission from ref. 54. Copyright 1994 Wiley.
Adapted with permission from ref. 55. Copyright 2001 Springer Nature.
Journal of Materials Chemistry B Review
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
Ju
ly
 2
02
0.
 D
ow
nl
oa
de
d 
on
 9
/1
5/
20
20
 5
:0
1:
24
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
7322 | J. Mater. Chem. B, 2020, 8, 7319--7334 This journal is©The Royal Society of Chemistry 2020
by Butler et al. has shown that during hydrolysis, the diffusion
coefficient of urease is increased, and the change is considered
to be a result of the formation of the local electric field
generated by the faster diffusion of NH4
+ ions.66 Furthermore,
when urease is introduced on the surface of a particle, the
biocatalytic conversion of urea can result in a diffusive motion
of the particles.67 However, to power urease motors, the conc.
required for the fuel is quite high, even though urease is relatively
robust and has a high turnover rate (kurease = 2.34  104 s1)
compared to other enzymes.68,69 As reported by researchers,
50 mM conc. is necessary for the particles to move and show
an increased diffusion coefficient,15,31,70 which is hard to be
achieved in normal biological fluids, except urine. However,
if the motors can be used in organs where there is higher urea
conc., they would be advantageous for biomedical application,
since particles will not show motion before reaching the
targeted area. For example, in the treatment of bladder cancer
or in intravascular drug/gene delivery, passing through the
bladder permeability barrier is considered to be tougher than
passing through the blood–brain barrier (BBB),71,72 and in such
a scenario, active particles might be helpful for the delivery
of drugs benefitting from the enhanced penetration efficiency
and a recent study by Sa´nchez et al.67 has already proved the
possibility of this strategy. However, the risk of introducing
urease into our body also needs to be considered.73
2.3 Glucose
Glucose is an essential nutrient for the human body and a
major energy source for cells delivered by the bloodstream. The
circulation of glucose in the bloodstream is mainly due to
exogenous nutrients (food) and endogenous glucose produc-
tion. The liver plays a major role in controlling the conc. of
blood glucose by balancing the uptake and storage and the
release of glucose via several metabolic pathways like glycogen-
esis, glycogenolysis and gluconeogenesis. In these procedures,
b-cells act as sensors and secret insulin for the regulation of
glucose.74 The normal conc. of glucose in the blood stream is
between 3.9 and 7.1 mM with the level varying throughout the
day.75 It is worth noting that the liver glucose conc. can be
influenced by the plasma glucose conc. in an opposite way,
i.e. when the plasma conc. increases, the liver shows a lower
conc. and vice versa.76 Moreover, in many solid tumor tissues,
the glucose level is lower than normal tissues (less than 1 mM),
because of the disorganized vasculature system and the
inefficient capillary bed.77–79 Glucose 1-oxidase (EC 1.1.3.4) is
a FAD-dependent enzyme consisting of two identical 80 kDa
subunits, widely used to catalyze the oxidation of b-D-glucose
(C6H12O6) to D-gluconolactone (C6H10O6) and H2O2 in the
presence of molecular O2.
80 Besides glucose oxidase (GOX),
three other types of enzyme can also oxidize glucose: glucose
dehydrogenases, quinoprotein glucose dehydrogenases and
glucose 2-oxidases. Although glucose dehydrogenases require
a soluble cofactor, quinoprotein glucose dehydrogenase is
not so stable and glucose 2-oxidases lack specificity; these
drawbacks of other enzymes make GOX a better choice for
applications.81 GOX was first discovered from Aspergillus niger,
and it can also be produced naturally in some fungi and insects.
As it is considered to be safe, GOX has been used as an additive
in food processing for decades, and also for the fabrication of
glucose biosensors.82 It has been coupled together with catalase
or other inorganic catalysts for cascade catalytic reactions, to
power MNMs. Recently, Zhang et al. reported a motor system for
tumor therapy, in which glucose oxidase (GOD) and manganese
dioxide (MnO2) were used as pair enzymes to consume glucose
in solid tumor, resulting in glucose depletion and significant
tumor suppression.83 Further research is required for biomedical
applications using glucose powered motors.
2.4 Adenosine 50-triphosphate (ATP)
It is well known that ATP is an essential cellular energy. It plays
an important role in many biological processes such as muscle
contraction, synthesis and degradation of biological molecules
and intracellular or extracellular signaling.84 ATP is synthesized
from adenosine diphosphate (ADP) and inorganic phosphate
(Pi) by F1F0–ATP synthase in an energy-requiring reaction. In
F1F0–ATP synthase, the F0 portion of the ATP synthase synthe-
sises ATP in biological systems and the F1 portion of ATP is
embedded in the membrane and catalyzes ion translocation,
while an electrochemical proton (or Na+) gradient provides
energy for ATP synthesis.55,85 The human plasma ATP conc.
has been measured, around 1 mmol L1,86 while the intracellular
conc. is maintained between 1 and 10 mmol L1.87,88 However, it
is noteworthy that the addition of extracellular adenosine (Ade)
is proved to be toxic to cells.89
ATP has been used as a fuel for many motor proteins found
in eukaryotic cells, for example ATP transports kinesins along
the microtubule filaments based on ATP binding, hydrolysis
and ADP release.90 ATP synthase itself has been known to be a
ubiquitous biological nanomotor, because of the rotation
motion during ATP synthesis.23,91 This biological nanomotor
has also been used in developing devices with multiple func-
tions in terms of monitoring, diagnosing and curing diseases.
Kinesin, as one of the ATP motor proteins, has been used
for making molecular shuttles for constructing nanoscale
assembly lines,6 and transporting and stretching DNA mole-
cules across a surface.92 However, the use of ATP might cause
the accumulation of ADP which inhibits the activity of these
biomotors,93 and hence the balance between enzymes and
substrates still needs to be addressed.
2.5 Other fuels
In the quest for physiologically relevant fuels, other chemicals
present in the biological system were also studied by researchers
as fuels for powering motors; for instance, a major extracellular
matrix (ECM) constituent, collagen, has been used as a fuel
for collagenase powered superparamagnetic nanoparticles, and
demonstrated enhanced tissue penetration.94 Triglyceride, a
major constituent of body fat in humans, which is also present
in blood for the bidirectional transference of adipose fat and
blood glucose from the liver,95 was recently used as a fuel for
powering motors based on lipase, and the study shows
that lipase motors can destroy triglyceride droplets while
Review Journal of Materials Chemistry B
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consuming triglyceride.96 Apart from them, a plethora of fuels
still needs to be investigated for powering MNMs.
3. Enzyme chemotaxis behavior
In nature, microorganisms control the directionality of their motion
by sensing the environment. One of the important behavioural
responses is called chemotaxis, meaning that microorganisms
can sense and move along the gradient of chemical species, to
find and locate a region with better living conditions.97,98
For example, bacteria have a molecular memory system to
help them move accordingly in a chemical gradient. In recent
years, the motion of enzymes has been widely studied and
reported to be due to binding or unbinding the substrate or by
chemotaxis behavior. In 2009, Schwartz et al. reported a complex
molecular motor driven by transcription substrates—nucleoside
triphosphates (NTPs) that undergo a biased movement along
a conc. gradient of the substrate for NTPs.102 Sen et al. also
reported the chemotaxis behavior in many models, in which
experiments used a microfluidic device with two inlets and one
outlet channel, with a fluorescently labeled enzyme in one inlet
and the substrate solution passing through the other as shown
in Fig. 2a. Using this device, the chemotaxis behavior of catalase,
urease and DNA polymerase was observed, and reported to move
toward a higher substrate conc. area.99 A study by Shelley D.
Minteer et al. of mitochondrial malate dehydrogenase and
citrate synthase using similar techniques also proved the
chemotaxis behavior among enzymes.103 For the study of enzy-
matic catalysis of enzymes involved in cascade reactions,
devices with multiple inlets were used, where enzymes involved
in cascade reactions were observed to move independently
along their own specific substrate gradient, while the chemo-
tactic assembly of enzymes was also observed under cytosolic
crowding conditions.104 In another research study, the chemo-
tactic behavior of enzymes has been used for the separation of
active and inactive enzymes with a two-inlet five-outlet micro-
fluidic device.68 Furthermore, the anti-chemotaxis behavior
of enzymes has also been reported both experimentally and
theoretically, showing that enzymes move away from their
substrate,105,106 which might be a result of different experi-
mental conditions, the observation time and the conc. difference
allowing them to be closer to the shape of the ultimate steady
state distribution of the enzyme, leading to a contrary result.107
For an in-depth mechanistic understanding of the chemotaxis
behaviour, several studies have analysed it in more detail. The
first theory for chemotaxis was proposed by Schurr et al.108 They
suggest that a thermodynamic force due to ligand binding might
drive the chemotaxis behaviour of enzymes, which has been
proved experimentally by Zhao et al.109 Recently, the potential
mechanisms of enzyme chemotaxis have been discussed in the
review by Gilson et al.,110 in which very detailed discussions
were given. First, a theoretical framework for mechanisms was
discussed based on the Fokker–Planck (FP) equation. Second,
the mechanisms based on the force-induced drift and position-
dependent diffusion coefficient studied in recent years were
summarized. Here these theories will not be discussed, however,
the mechanism of chemotactic behaviour of EPMs could be
essential in EPM based research.
With the development of EPM systems, the effect of chemo-
taxis behavior of enzymes on EPM systems needs to be
addressed. Recently, Battaglia et al. reported asymmetric poly-
mersomes powered by glucose oxidase and catalase, and in this
system, motors were observed in response to an external
gradient of glucose and move toward regions with higher conc.
of substrate glucose according to the superdiffusional
behaviors in the presence of a gradient (Fig. 2c).101 Similar
behavior was also reported by Sen et al.69 In liposome based
enzyme driven motors, the same group observed that the motion
of the motor is related to the enzyme-catalysis-induced positive
chemotaxis and solute–phospholipid-based negative chemotaxis
of enzymes attached to the liposome model.111 In this paper,
the propulsion mechanism of this EPM was hypothesized and
proved to be a result of enzyme-catalysis-induced positive
chemotaxis and solute–phospholipid-based negative chemo-
taxis. Recently, work from our group has made use of chemo-
taxis behavior as a strategy for motors to deliver doxycycline for
the treatment of periodontal disease, and the study showed
that the enzyme powered micromotor can move with controlled
directionality because of the substrate gradient produced by
phagocytes (Fig. 2b).100 We believe that the use of chemotaxis
behavior for enzyme powered MNMs can be an ideal approach
for developing the next generation of nanocarriers for bio-
medical applications, however, mechanistic studies based on
Fig. 2 (a) Schematic representation of the Y-shaped microfluidic channel
used for chemotactic studies of ensembles of enzyme molecules.99
(b) Schematic overview of the chemotactic model. Raw 264.7 cells before
and after being triggered by PMA (green: actin cytoskeleton, blue: cell
nuclei).100 (c) Schematics of the proposed mechanisms of asymmetric
polymersome chemotaxis, which consist of alternative running and
reorientation events.101 Adapted with permission from ref. 99. Copyright
2013 American Chemical Society. Adapted with permission from ref. 100.
Copyright 2020 Wiley. Adapted with permission from ref. 101. Copyright
2017 American Association for the Advancement of Science.
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EPMs are necessary for further understanding of these motors
in particular when placed in biological environments.
4. Enzyme powered motors (EPMs)
The first example of enzyme powered artificial systems was
demonstrated by Mano and Heller by binding glucose oxidase
and bilirubin oxidase on either side of a carbon fiber at the
water–O2 interface.
17 Later in 2007, Feringa et al. fabricated
carbon nanotubes covalently functionalized with glucose
oxidase and catalase enzymes, reaching speeds up to 0.8 cm s1
in the presence of glucose and oxygen.112 These demonstrations
laid the platform for the fabrication ofmicro/nanomotors (MNMs)
powered by enzymes by various research groups (Fig. 3). As
discussed in the previous section, there is a plethora of fuels
available in the biological environment that can be exploited as
fuels to power micro/nanomotors (MNMs) with the help of
enzymes, using them as substrates for carrying out catalytic
reactions and thus providing the propulsion force. This section
will showcase the enzymes utilized to power MNMs to date
together with the main focus on using biologically relevant fuels
together with their fabrication and propulsion mechanism.
4.1 Catalase based EPMs
Catalase decomposes H2O2 to produce oxygen that can power
MNMs based on the bubble propulsion mechanism. The first
report of using catalase as a sole enzyme to drive micromotors
was demonstrated by Sanchez et al., with the help of a roll up
technique. The fabrication was carried out using thin Au/Ti
films rolled up with a covalently bound catalase enzyme that
could reach speeds up to 8 body-lengths per s, much higher
than the corresponding Pt-based micromotors.120 Later, the
same group used mesoporous silica clusters (MSC) to fabricate
micromotors coated with catalase enzymes by EDC–NHS func-
tionalization and Ni by electron beam deposition on either side
to provide them with directionality using magnetic guidance
(Fig. 4a).121 Furthermore, they fabricated nanomotors with hollow
mesoporous silica nanoparticles (HMSNPs) due to their superior
biocompatibility on account of the glutaraldehyde linkage of
catalase on one side of the HMSNPs. These nanomotors with a
size of around 390 nm were observed to self-propel due to the
chemo-phoretic mechanism arising due to a product conc.
gradient around the surface owing to the asymmetric bio-
catalytic reaction.114 In order to reduce the size of nanomotors
for biomedical applications Sanchez et al. also fabricated motors
of a size of around 100 nm powered by a similar mechanism.18
Sen et al., in 2015, used polystyrene beads to anchor the catalase
enzyme by biotin–streptavidin linkage and showed an enhanced
diffusivity of the beads and the directional migration along the
substrate gradient by enzyme catalysis (Fig. 4b).69
In this regard, Wilson et al. fabricated polymer based
nanomotors using the bottom-up approach involving supra-
molecular chemistry called stomatocytes.122 The bowl shaped
stomatocytes were formed by the controlled shape transforma-
tion of polymeric vesicles.46 These structures have an opening
on one side providing the necessary asymmetry for nanomotor
application and can be encapsulated with enzymes to power
them (Fig. 4d).123 The polymeric structures provide a soft
interface to cells, do not contain hard metal surfaces, provide
easy functionalization and contain polyethylene glycol (PEG)
Fig. 3 Schematic of enzymes reported to power micro/nanomotors
(MNMs) arranged in an ascending order of turnover number (kcat):
trypsin,113 glucose oxidase (GOx),114 GOx coupled with catalase,115,116
acetylcholinesterase (AChE),117 urease,20,70,114,118 and catalase.18,69,114,119
Adapted with permission from ref. 20, 69, 113–116 and 118 and 119.
Copyrights 2010, 2015, 2016, and 2017 American Chemical Society.
Adapted with permission from ref. 117. Copyright 2019 Springer Nature.
Adapted with permission from ref. 70. Copyright 2018 Wiley. Adapted with
permission from ref. 18. Copyright 2017 Elsevier.
Fig. 4 Designs for catalase powered MNMs. (a) Mesoporous silica
nanoclusters with magnetic control bound to catalase on one side,121
(b) polystyrene beads coated with catalase by biotin–streptavidin linkage,69
(c) biocompatible hydrogel fabricated by PEGDA and dextran,124 (d) poly-
meric (PEG-b-PS) stomatocytes encapsulated with enzymes,115 (e) biode-
gradable polymeric (PEG-b-PDLLA) nanotubes coated with catalase,125
(f) organoclay/DNA protocells encapsulated with enzymes,126 and (g) poly-
meric protocells encapsulated with catalase for autonomous motion.127
Adapted with permission from ref. 121 and 125. Copyrights 2015, 2018 Royal
Society of Chemistry. Adapted with permission from ref. 69 and 115.
Copyrights 2015 and 2016 American Chemical Society. Adapted with
permission from ref. 124 and 127. Copyrights 2018 Wiley. Adapted with
permission from ref. 126. Copyrights 2018 Springer Nature.
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that is highly biocompatible.128 The stomatocytes were encapsu-
lated with catalase in the stomach that could propel in the
presence of H2O2 with speeds up to 60 mm s
1 due to the
expulsion of oxygen bubbles produced through the opening,
providing forward thrust. In the same study, stomatocytes were
encapsulated with a two enzyme system comprising GOx and
catalase that participates in a cascade reaction in the presence of
glucose as a substrate and propels due to self-diffusiophoresis.115
In order to have a completely biodegradable polymer, a
poly(ethylene glycol)-block-poly(D,L-lactide) (PEG-b-PDLLA) diblock
copolymer was used to fabricate tubular structures functionalized
with catalase, showing enhanced diffusion (Fig. 4e).125 PEG–PDLLA
was also used to fabricate stomatocytes with spatial control for
functionalization by providing two different functional groups
on the inside and outside of stomatocytes. The stomach of the
stomatocytes was functionalized with GOx and catalase, showing
propelled motion with speeds reaching up to 15.8 mm s1 in the
presence of glucose.129 The same group also fabricated asym-
metric hydrogel based micromotors composed of dextran and
poly(ethylene glycol) diacrylate (PEGDA) with entrapped catalase
(Fig. 4c). The low molecular weight dextran can diffuse into
hydrogels upon UV polymerization forming an opening for
bubble propulsion, when H2O2 is decomposed by catalase in
the PEGDA phase reaching speeds up to 100 mm s1.124 Further-
more, control over the speed of these micromotors was achieved
by controlling the surface of the opening.130
Protocells have also been fabricated by encapsulating
catalase in the lumen of a biotinylated polymersome. In the
presence of H2O2 the force generated by the enzymatic reaction
on the surface of protocells was enough to break adhesive
contacts between the polymersome and the surface, to drive their
autonomous motion, mimicking the formation and breakage of
adhesive contacts as showcased by mammalian cells (Fig. 4g).127
In another study, catalase containing organoclay/DNA semi-
permeable microcapsules were fabricated that displayed oxygen
gas bubble dependent buoyancy (Fig. 4f).126 When the same
system was co-encapsulated with GOx and catalase a sustained
vertical oscillatory movement was established due to antagonistic
bubble generation and depletion. Such systems could be used for
the flotation of macroscopic objects, self-sorting of mixed proto-
cell communities and delivery of a biocatalyst from an inert to
chemically active environment.126
4.2 Urease based EPMs
In order to overcome the use of non-biocompatible fuels such
as H2O2 required for catalase driven systems and the bubble
propulsion mechanism, researchers have exploited the urease
enzyme to power motion through the use of biocompatible
fuels. Sen et al. used gold (Au) nanoparticles anchored with
urease enzymes and used them as pumps that could move
tracer particles in the presence of their substrate urea.131 The
observed migration of tracer particles was due to fluid pumping
caused by the enzymatic reactions. Sanchez et al., later fabri-
cated nanomotors using HMSNPs covalently bound to urease
enzymes on one side to create a Janus structure (Fig. 5a).
The HMSNP nanomotors were observed to have an enhanced
diffusion coefficient due to the chemophoretic mechanism
arising from the catalytic reaction of urease in the presence of
urea.114 In addition, the control over urease powered HMSNPs
reaching speeds up to 5 body-lengths s1 was achieved by the
addition of inhibitors such as Ag+ or Hg2+ for modulating the
enzymatic activity (Fig. 5b).20 The modulation of the enzyme
activity resulted in manipulating the mechanical output on the
motors, thereby gaining control over its speed. The inhibition
process was reversible upon the addition of dithiothreitol (DTT)
due to competitive binding, resulting in control over the start
and stop motion of the micromotors. Furthermore, the incor-
poration of magnetic materials helped in gaining control over
the directionality of the as fabricated micromotors. Ultrasmall
tubular silica nanojets with 220 nm diameter and lengths
ranging from 3 to 40 mm were also fabricated by binding urease
through glutaraldehyde linkage molecules (Fig. 5c).118 The
decomposition of urea caused an internal flow that extended
to an external fluid through the opening, thus giving rise to self-
propulsion. The speed of the motors reached up to 10 mm s1
and was observed to be dependent on the conc. of the
fuel, fitting well with Michaelis–Menten enzymatic kinetics.
Interestingly, for this system when the enzyme was functionalized
Fig. 5 Urease powered motors. (a) JHMSNP nanomotors powered by
urease due to the chemo-phoretic mechanism arising from the conc.
gradient obtained from the asymmetric catalytic reaction,114 (b) meso-
porous silica microparticles powered by urease with control over motion
and directionality,20 and (c) silica tubular nanojets fabricated by covalently
binding urease.118 Adapted with permission from ref. 20, 114 and 118.
Copyrights 2015 and 2016 American Chemical Society.
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on the outside of the nanotubes, only Brownian motion was
observed showcasing the need for internal flows for propulsion.
4.3 Glucose oxidase (GOx) based EPMs
Glucose oxidase catalyzes the oxidation of glucose to D-glucono-
1,5-lactone and H2O2 that can be used in tandem with enzymes
such as catalase for powering nanomotors. The first example of
using GOx in tandem with bilirubin oxidase (BOD) to power
artificial systems was shown by Mano and Heller in 2005.17 In
this system, one side of the fibre was decorated with GOx
carrying out the oxidation of glucose and another side by
BOD carrying out the reduction of oxygen (Fig. 6a). This
reaction results in the travelling of generated protons in the
electrical double layer of the fibre, dragging water molecules
with them and thus propelling the nanomotor in the opposite
direction. Since then, there have been many MNMs fabricated
by using GOx and catalase to power motion as discussed in
catalase powered systems. Here, we will discuss a few more
examples of MNMs that are driven by the self-diffusiophoresis
mechanism. Stadler et al. fabricated micromotors featuring a
Janus architecture with a poly(dopamine) (PDA)-coated silica
(SiO2/PDA) particle as the core, followed by PEGylation with
poly(L-lysine)-grafted-poly-(ethylene glycol) (PLL-g-PEG) on one
side and immobilizing GOx and catalase on the other side.
The micromotors were observed to have enhanced diffusion
dependent on glucose conc. The locomotion was based on self-
diffusiophoresis due to the generation of a conc. gradient of
molecules accomplished by the conversion of one molecule
into two.116 Later, a similar system was modified with Pt
nanoparticles instead of catalase enzymes that showcased a
100% increase in diffusion properties due to a higher density of
GOx immobilization and no net loss in enzyme activity for
metallic nanoparticles. The system was also co-immobilized
with trypsin that cleaves peptide bonds at the carboxylic acid
sites of amino acids coated with superparamagnetic manga-
nese ferrite nanoparticles (MF-NPs) (Fig. 6b). The microswim-
mer, could thus be propelled by two fuel sources and could be
guided remotely with the help of a magnet, hence, giving rise to
directionality.113 He et al. fabricated carbonaceous nanoflasks
(CNF) that could self-propel in the presence of glucose and the
directionality could be premeditated depending on the surface
wettability of the nanoflasks (Fig. 6c). The hydrophilic CNF
exhibited backward movement dominated by a local glucose
gradient and hydrophobic CNF exhibited forward movement by
the generated local glucose acid gradient.132 Simulation results
revealed that the hydrophilic nanoflask motor generates a
puller-like flow field, whereas the hydrophobic motor creates
a pusher-like flow field resulting in backward and forward
movement, respectively. In the same year, his group also
fabricated nanomotors by grafting polymer brushes on one
side and GOx on the other side of Au nanoparticles (Fig. 6d).
These particles were observed to have positive chemotaxis
towards the glucose gradient with speeds reaching up to 120
body-lengths s1. The grafted polymer brush provided the
motor with improved translational diffusion resulting in bac-
teria with swarming behavior.133
4.4 Other EPMs
Although the majority of research is focused on the above-
mentioned enzymatic systems, researchers have used other
enzymes for powering motion. One such example are lipases,
an industrially important enzyme that hydrolyze carboxylic ester
bonds in hydrophobic compounds such as triglycerides.134
Recently, lipase was immobilized covalently on MSNPs and were
observed to have enhanced Brownian motion in the presence of
dissolvable triglyceride solution (Fig. 7a). The lipase enzyme had
two functions; (a) powering the motor and (b) to degrade
triglyceride (tributyrin).24 At the same time, another group also
reported four different types of micromotor fabricated with
poly(glycidylmethacrylate)/polystyrene (PGMA/PS) particles and
using hydrophobic interactions to bind lipase (Fig. 7b).135
The micromotors revealed substrate conc. dependent enhanced
diffusion and facilitated enzymatic reactions. The propulsion
mechanism of both the above-mentioned motors was based
on a product gradient due to the degradation of triglyceride
molecules.
Apart from lipase, adenosine 50-triphosphatase has also been
studied by Sen et al. to fabricate active phospholipid vesicles
using the hydration assembly of L-a-phosphatidylcholine (EPC)
in the presence of ATPase (Fig. 7c).136 These biocompatible
phospholipid vesicles exhibited enhanced diffusion in the
presence of their substrate ATP by hydrolyzing the phosphate
bonds. In the same study, similar results were also obtained for
Fig. 6 Glucose oxidase powered motors. (a) Carbon fibre decorated with
GOx on one side and BOD on other side resulting in bioelectrochemical
propulsion,16 (b) double fueled Janus swimmers decorated with GOx,
trypsin, Pt and Mn–Fe nanoparticles with magnetic guidance,113 (c) surface
wettability directed carbonaceous nanoflasks with GOx and catalase,132
and (d) polymer brush functionalized Au nanoswimmers with swarming
chemotactic behavior.133 Adapted with permission from ref. 16. Copyrights
2014 Royal Society of Chemistry. Adapted with permission from ref. 113
and 132. Copyrights 2017 and 2019 American Chemical Society. Adapted
with permission from ref. 133. Copyrights 2019 Wiley.
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acid phosphatase (AP) enzymes that were bound to vesicles
using a biotin–streptavidin linkage.136
4.5 Biologically relevant fluid driven motors
Until now we have discussed EPMs using biocompatible fuels such
as glucose, physiologically relevant urea and H2O2; herein MNMs
powered by another important biologically relevant fuel i.e. acidic
conditions prevalent in stomach and tumor cells together with
water will be discussed. The first acidic environment based on
tubular micromotors was fabricated using polyaniline with the zinc
(Zn) coating on the outer surface and inner surface of the tube,
respectively (Fig. 8a). A spontaneous redox reaction was carried
out on the Zn surface, thereby generating hydrogen (H2), and the
as-produced H2 bubbles provided forward thrust to the tube
and hence propelling them at a speed of 100 body-lengths s1.11
Later the system was modified into double conical micromotors
fabricated only with Zn for higher capacity, combinatorial delivery
of cargoes, autonomous release of encapsulated payloads, and self-
destruction.137 Simultaneously, magnesium (Mg) based micromo-
tors were also fabricated that could propel in the presence of H2O
and acid. Wang et al. fabricated Mg based Janus micromotors that
self-propelled in seawater without an external fuel due to the
oxidation of the Mg surface which reduces water to H2 bubbles
(Fig. 8c). The micromotor was coated with Ni for magnetic
guidance and Au for increasing the propulsion efficiency associated
with the microgalvanic corrosion mechanism.138 The system was
further modified to fabricate tubular micromotors that could
propel in the gastrointestinal tract at a speed of 60 mm s1 due
to H2 bubbles produced from the water-based reaction (Fig. 8b).
Furthermore, Mg based micromotors were also demonstrated to
propel under acidic conditions by a spontaneous reaction between
the Mg microsphere and the surrounding protons generating
H2 bubbles providing efficient micromotor thrust (Fig. 8d).
139 With
respect to acidic conditions, calcium carbonate (CaCO3) Janus
micromotors were fabricated to achieve motion under slightly
acidic conditions found in the tumor microenvironment with
velocities of 1.8 mm s1 (Fig. 8e).140 The propulsion mechanism
was based on self-diffusiophoresis due to the controlled decom-
position of CaCO3 into Ca
2+, HCO3
, OH and H+ ions, thereby
inducing diffusioosmotic flows generated by the difference in
diffusion coefficients of the ions produced.141
5. Biomedical applications of EPMs
Enzymatically powered motors can propel themselves through
an aqueous solution by self-generated gradients and gas
bubbles. With recent advancements, MNMs have been observed
to have active motion using fuels present in bodily fluids or
physiologically relevant molecules that could be used by
enzymes as substrates. In this section, we will discuss examples
for EPMs based on materials used for fabrication and discuss
their relevant biomedical applications.
5.1 Mesoporous silica based EPMs
Mesoporous silica offers various advantages in terms of easy
synthesis, high loading capacity, large surface area and good
biocompatibility.142 They are easy to functionalize with the
Fig. 7 Other enzyme powered motors. (a) Mesoporous silica nanoparticles
covalently immobilized with lipase for nanomotor application,24 (b) enzyme
immobilized particles showcasing different micromotor configurations
immobilized with lipase,135 and (c) ATPase and AP as membrane bound
enzymes for enzyme powered vesicles.136 Adapted with permission from
ref. 24. Copyrights 2019 Wiley. Adapted with permission from ref. 135.
Copyrights 2019 Elsevier. Adapted with permission from ref. 136. Copyrights
2019 American Chemical Society.
Fig. 8 Biologically relevant fluid driven systems. Acid driven micromotor
systems based on (a) Zn11 and (b) Mg;139 water driven systems (c) Janus
Mg,138 (d) tubular Mg base micromotors147 and (e) calcium carbonate
based Janus micromotors driven by acidic conditions in the tumour
microenvironment.140 Adapted with permission from ref. 11 and 147.
Copyrights 2012 and 2016 American Chemical Society. Adapted with
permission from ref. 138. Copyrights 2013 Royal Society of Chemistry.
Adapted with permission from ref. 139. Copyrights 2017 Wiley. Adapted
with permission from ref. 140. Copyrights 2016 Springer Nature.
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possibility of various surface chemistry modifications, high
potential for the physical entrapment of particles and have
been clinically approved by FDA for biomedical applications.143
In 2012, MSNs were used for the fabrication of nanomotors for
capture and cargo transport that was powered by the catalase
enzyme. The asymmetry to the nanomotor was achieved by
coating with Au on one side that was used for functionalizing
single-stranded DNA and the other side was functionalized with
catalase that provided the driving force in the presence of a low
conc. of H2O2.
144 The system was able to capture cargo (DNA
functionalized particle) with the help of analyte DNA strands
whose ends are complimentary to the DNA strands on nano-
motors and cargoes, thereby acting as a bridge due to the high
selectivity of the DNA hybridization process.144 The system was
envisioned to be integrated in lab-on-chip devices for biome-
dical diagnostic applications. Wang et al. used MSNs to fabri-
cate acoustically propelled nanomotors that could release
insulin in the presence of glucose.145 Even though the system
was not powered by enzymes, they were used to fabricate
glucose responsive nanovalves based on phenylboronic acid
(PBA)–GOx supramolecular nanostructures. The MSN particles
were loaded with insulin gated with (PBA)–GOx nanovalves to
prevent the unloading of insulin. GOx present in the nanovalves
produces H2O2 in the presence of glucose, thereby decreasing
the pH and cleaving the C–B bond and thus releasing the
loaded insulin. The use of active propelled motion by ultra-
sound helped in increasing the insulin release efficiently.145
Sanchez et al. coated MSNs with urease enzymes for powering
the DOX loaded nanobots in the presence of urea (Fig. 9a).
The nanobots could self-propel in ionic media and showed
improved effect on HeLa cells in the presence of urea when
compared to its passive counterparts, due to a synergistic effect
between improved drug release kinetics and ammonia produc-
tion by the catalytic decomposition of urea.70 In another study,
the above system was modified to the target by specific inter-
action and to reduce the proliferation of 3D bladder cancer
spheroids found in the urinary bladder (Fig. 9b).146 For this, the
MSN was modified with urease for powering the system and
bound with an anti-FGFR3 antibody. The enhanced diffusion of
the nanomotors at biologically relevant conc. of urea allowed
them to explore a greater area in comparison to passive diffu-
sion, thus, improving the chances of interaction between the
antigen and the antibody and decreasing the proliferation of the
spheroids.146 Furthermore, the urease powered MSN was further
used for the delivery of DOX to HeLa cells using a pH gated
system (Fig. 9c). The nanomotors were loaded with DOX grafted
with benzimidazole groups on the outer surface, and capped by
the formation of inclusion complexes between benzimidazole
and cyclodextrin-modified urease (CD-U).148 Benzimidazole
CD-U nanovalves prevented the release of DOX at physiological
pH, but in the presence of acidic pH prevalent in the tumor
microenvironment the protonation of benzimidazole causes
the subsequent dethreading of inclusion complexes thereby
releasing the cargo. Cellular studies revealed that the presence
of active nanomotors enhanced both tumor internalization and
intracellular cargo delivery.148 Ramo´n Martı´nez-Ma´n˜ez et al.
modified the above system by powering the motors with the
catalase enzyme and glutathione (GSH) responsive valves for
cargo delivery (Fig. 9d). Glutathione is a tripeptide that carries
out redox reactions and is present in high conc. in intracellular
compartments.150 In brief, MSN particles were attached with
Au nanoparticles on one side that were further covalently
functionalized with catalase. Later, the MSN scaffold was loaded
with DOX and capped with disulfide linked chains.149 In the
presence of H2O2 the MSN nanomotors showed enhanced diffusion
resulting in higher internalization in HeLa cells and due to the
presence of GSH, the disulfide bonds are broken thereby releasing
DOXmolecules. The latter two systems could sense the environment
and release the cargo molecules in the presence of a stimulus thus
displaying features essential for biomedical applications.
5.2 Polymer based EPMs
Recently, polymers have attracted attention for the fabrication
of MNMs due to easy functionalization, ease of scaling up,
and appropriate physicochemical properties for biomedical
applications with good biocompatibility.151 In addition, they
can be self-assembled into supramolecular structures that can
provide a soft interface to cells in comparison to hard metal
surface based MNMs together with good biodegradability. He
et al. fabricated Janus capsules loaded with DOX by template-
assisted polyelectrolyte layer-by-layer (LBL) deposition using
poly(styrenesulfonate) sodium salt (PSS) and poly(allylamine
hydrochloride) (PAH).152 This was followed by the deposition of
Au, Cr and Ni, with Au coated with catalase enzymes that
powered the motors by the biocatalytic decomposition of H2O2.
The Janus capsule was observed to swim at 25 mm s1 and was
directed towards HeLa cells using an external magnetic field and
upon application of near-infra red (NIR) light, it induced the
shell breakage of Au particles thereby releasing DOX molecules.
Such systems provide self-driving with navigation capabilities
and perform drug loading and targeted transportation together
with remotely controlled release in the vicinity of cells.152 Using a
similar technique, biodegradable poly-L-lysine hydrochloride/bovine
serum albumin multilayered microtubes were fabricated with the
integration of a thermal-sensitive gelatin hydrogel containing Au
nanoparticles, DOX and catalase enzymes.153 The catalase reaction
propelled themotors, with Au increasing the local temperature upon
illumination with NIR light, thereby releasing DOX molecules.
In addition to this, the protein based structure provided high
biodegradability in the presence of a-chymotrypsin and hence
satisfying all the requirements for biomedical applications.153
Battaglia et al. fabricated chemotactic vesicles based on
polymersomes encapsulated with GOx alone or in combination
with catalase exhibiting self-propulsion in response to a glucose
gradient. The polymersomes upon further functionalization
with low-density lipoprotein receptor-related protein 1 (LRP-1)
showed a four-fold increase in blood brain barrier crossing
(Fig. 10a).101 The asymmetric polymerosome propulsion velo-
city was directly proportional to the glucose gradient and larger
particles were observed to have better binding affinity to the
vessels due to minimized rotational diffusion.101 In 2019,
Stadler et al. fabricated biocompatible self-propelled swimmers
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functionalized with collagenase enzymes for using collagen as a
fuel and supermagnetic nanoparticles that can impart heat
generation and used calcium for triggering the motion
(Fig. 10b).154 Collagenase enzymatically breaks collagen in the
extracellular matrix and the asymmetry required for self-
diffusiophoretic motion is provided by the calcium gradient
Fig. 9 Mesoporous silica based EPMs. (a) Urease powered motors for DOX delivery showing a decrease in cell viability with increasing urea conc.70
(b) Urease powered motors with antibodies against 3D bladder cancer spheroids showing decreased cell viability corresponding to urea conc.146
(c) Schematic representation of benzimidazole and cyclodextrin-modified urease powered nanomotors (i), showing internalization into HeLa cells via
TEM (ii) and high resolution confocal images with different signals corresponding to the WGA membrane marker (green), DNA-marker Hoechst 33342
(blue), and DOX (red).148 (d) Schematic representation of the performance of nanobots with self-propulsion and glutathione-responsive cargo delivery
capabilities inside a cell.149 Adapted with permission from ref. 70. Copyrights 2017 Wiley. Adapted with permission from ref. 146 and 148. Copyrights 2018
and 2019 American Chemical Society. Adapted with permission from ref. 149. Copyrights 2019 Royal Society of Chemistry.
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that also enhanced the enzymatic activity. The microswimmers
enhanced penetration into cancer cell spheroids and further
resulted in a decreased fraction of live cells when exposed to an
alternate magnetic field due to heat generation.154 With respect to
tumor cell penetration, Wilson et al. fabricated both small and
ultra-small stomatocytes encapsulated with the catalase enzyme in
the size ranging around 150 nm (Fig. 10c).155 The smaller size in
comparison to normal stomatocytes resulted in increased cellular
uptake in the presence of H2O2 as a fuel due to the enhanced
permeation and retention (EPR) effect. These systems can be
further extrapolated as cargo delivery vehicles or for targeted
delivery of drugs. In this context, poly(lactic-co-glycolic acid)
microspheres were fabricated for the delivery of the doxycycline
drug, used for the treatment of periodontal disease to prevent
bacterial infection. The micromotors were powered with cata-
lase enzymes that could induce motion and provide directional
motion in the presence of a H2O2 gradient produced by
macrophage cells incubated with phorbol-12-myristate-13-
acetate.100 All the above examples showcase the advantages of
polymer based MNMs powered by enzymes and warrant further
investigation for their biomedical application.
5.3 Inorganic oxides and MOF based EPMs
Silica materials are well studied and are reported to have
negligible cytotoxicity towards cell proliferation with good
biocompatibility at adequate doses.156 Fischer et al. fabricated
micropropellers using SiO2 particles coated with nickel and
functionalized with the urease enzyme. The micropropellers
were able to penetrate the mucin gels by increasing the pH
locally due to the biocatalytic reaction of urease enzymes which
liquefies the mucus and also provides the driving force.160 The
micropropellers were directed by an external magnetic field and
could possibly be used for drug delivery applications by over-
coming the limitations of acidic conditions present in the
stomach.160 CaCO3 is another example for inorganic oxide that
is highly biocompatible, has low costs, is highly reproducible
and can be easily loaded with drug molecules that could
be released under acidic pH conditions in the tumor micro-
environment. With regards to micromotors, CaCO3 has been
studied to power microspheres loaded with enzyme creatine
phosphate kinase (CPK) that produce ATP. The microspheres
once bound to microtubules were able to glide with an average
velocity of 92  7 nm s1 on a surface coated with kinesin and
used for cargo delivery in the presence of ADP and CP.161 In
another example, CaCO3 cores modified with the urease enzyme
on one side for powering motors, hyaluronic acid on another
side for targeting and loaded with camptothecin for the anti-
tumor effect (Fig. 11a).157 The nanomotors showed enhanced
penetration and cellular uptake into tumor cells. Upon reaching
the tumor cells the disintegration of the core due to the presence
of acidic pH conditions aids in localized delivery to CPT mole-
cules thereby resulting in increased necrosis. Using such nano-
motors is a feasible strategy to boost the antitumor efficacy by
promoting the local accumulation, deep tumor penetration,
tumor cell capture and the intracellular release of chemotherapeutic
drugs.157 Recently, metal organic frameworks (MOF) have gained
interest due to their porous structure and disintegration based on
pH stimuli.151 Ma et al. fabricated MOF based nanomotors by
encapsulating them with photosensitizers to generate cytotoxic
1O2 for efficient photodynamic therapy (PDT), powered by GOx
and catalase that caused starvation of cells due to the utilization
of glucose (Fig. 11b).158 The catalase enzyme also decomposed
H2O2 present in the cells to produce
3O2 molecules that help in
the generation of 1O2 molecules. Overall, the active system
increased the cellular uptake by increasing the diffusivity by
27% and the synergistic effects of PDT and starvation therapy
resulted in decreased cell viability of HeLa cells accounting
to 73%, far better than individual therapies used in the study.158 In
another study, the pH regulated delivery of DOX molecules to HeLa
cells was carried out using a MOF based system. The micromotors
Fig. 10 Polymer based EPMs. (a) Schematic representation of a chemo-
tactic polymersome using a combination of copolymers. The polymer-
somes encapsulate glucose oxidase and/or catalase enzymes (i), percentage
of the injected dose found in the rat brain parenchyma and the capillary
fraction 10 min after the carotid artery in situ perfusion of polymersomes
loaded with Gox + Cat and empty, as well as pristine asymmetric polymer-
somes loaded with Gox and Cat (ii) and (iii) immunofluorescence histologies
of rat hippocampus sections of animals treated with asymmetric polymer-
somes loaded with Gox + Cat.101 (b) Schematic representation of collage-
nase loaded polymeric swimmers (i) and their penetration into spheroids (ii),
CLSM images of the spheroids aged over 24 h and 48 h, upon addition of
polymeric nanomotors for 24 h. The blue channel represents the stained
spheroids, and the green channel represents the swimmers (iii) and swim-
mers located inside the spheroid (represented as % of internalization),
determined as the percentage of green pixels in the spheroid area of images
(iv).154 (c) Schematic representation of enhanced cellular uptake of ultra-
small stomatocytes due to the EPR effect.155 Reproduced with permission
from ref. 101. Copyrights 2017 American Association for the Advancement
of Science. Reproduced with permission from ref. 154 and 155. Copyrights
2019 American Chemical Society.
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consisted of succinylated b-lactoglobulin and the catalase enzyme
superassembled onto MOF particles (Fig. 11c).159 In the presence of
neutral pH, succinylated b-lactoglobulin is permeable throughwhich
H2O2 can reach the catalase enzyme to power the nanomotors. Once
acidic pH conditions were encountered in tumor cells, succinylated
b-lactoglobulin undergoes reversible gelation that seizes the
motion of micromotors and due to degradation it releases the
encapsulated DOX molecules to HeLa cells as observed via
deconvolution microscopy.159
To the best of our knowledge we have discussed all the well-
known enzyme powered motors and their biomedical applica-
tions. Apart from these, there are few examples of MNMs based on
Zn and Mg metals studied by Wang et al. that can power motion
in the presence of acidic pH conditions present in the stomach
and utilized for biomedical applications.162–165 However, these
MNMs are not the focus of this review and are hence only briefly
discussed here, to showcase the other possibilities.
6. Outlook and future perspectives
Enormous progress has been made in the field of EPMs with
ample proof-of-concept studies exhibiting their biomedical
applications. To realize the full potential of such systems a
number of factors require to be addressed. First, the use of
biocompatible and biodegradable components that comprise
the body parts of the EPM is to be optimized. Even though the
use of stimuli responsive polymers can be an ideal solution, their
specific interaction with tissues and cells needs to be studied.
Second, there is a need of exploring fuels present under physio-
logically relevant conditions; until now only a few fuels have
been studied and there is a plethora of fuels available that has
not yet been explored. Furthermore, currently, many studies
have been carried out using a relevant conc. of physiologically
present fuels by externally supplying them. It is the need of the
hour to test EPMs using endogenously produced fuels that can
act as substrates for enzymes to power them. Third, for taking
EPMs towards more application-oriented studies, a better under-
standing is required of their propulsion mechanism and they
need to be engineered for enhanced stability in the bodily fluids
as current systems exhibit lower efficiency. Fourth, it is required
to throw light and gain deep insights and knowledge on the
shape and geometry of EPMs, which is best suited for the
proposed biomedical applications together with control over
motion and directionality for targeted therapy. Fifth, a thorough
investigation of the bioavailability, retention, toxicity, and ther-
apeutic efficacy of EPMs and their tracking in real world clinical
applications is required for true in vivo biomedical applications.
The current advancements only form the tip of the iceberg and
all the above issues warrant immediate research to understand the
role of EPMs in complex biological environments to make them
truly applicable for biomedical applications. To achieve this, a close
collaboration is required between researchers in the field of medi-
cine, materials science, robotics, biology, nanotechnology and chem-
istry to expand the use of EPMs in real world applications.
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